Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Holders of 5% or more of CDTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cidara Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Group Inc | 13G | 6.38%2.01M shares | New | Jan 30, 20261 filing | Jan 30, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
60 Schedule 13D and 13G filings on Cidara Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20264:32 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 1.40%450.0K shares | −4.80 ppfrom 6.20%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:30 PM ET | BCLS Fund III Investments, LP | 13G/A | 0.00%0 shares | −9.99 ppfrom 9.99%Below 5% | Dec 31, 2025 | SEC |
| Feb 13, 20266:11 PM ET | Vivo Opportunity Fund Holdings, L.P.and 3 others | 13G/A | 0.00%0 shares | −4.60 ppfrom 4.60%Below 5% | Jan 7, 2026 | SEC |
| Jan 30, 20261:25 PM ET | Vanguard Group Inc | 13G | 6.38%2.01M shares | New | Dec 31, 2025 | SEC |
| Jan 9, 20264:45 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 0.00%0 shares | −10.70 ppfrom 10.70%Below 5% | Jan 7, 2026 | SEC |
| Nov 17, 20254:39 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 10.70%3.37M shares | 0.00 ppfrom 10.70% | Nov 13, 2025 | SEC |
| Nov 14, 20254:39 PM ET | Commodore Capital LPand 3 others | 13G/A | 2.00%585.0K shares | −3.50 ppfrom 5.50%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:34 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 3.30%961.2K shares | −2.30 ppfrom 5.60%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:30 PM ET | BCLS Fund III Investments, LP | 13G/A | 9.99%3.02M shares | 0.00 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Nov 14, 20254:23 PM ET | TCG Crossover GP II, LLCand 2 others | 13G/A | 0.00%0 shares | –Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:12 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 6.20%1.58M shares | −1.40 ppfrom 7.60% | Sep 30, 2025 | SEC |
| Nov 10, 20254:40 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 10.70%3.37M shares | −2.60 ppfrom 13.30% | Nov 6, 2025 | SEC |
| Oct 17, 20256:40 PM ET | BlackRock, Inc. | 13G/A | 4.60%1.16M shares | −0.90 ppfrom 5.50%Below 5% | Sep 30, 2025 | SEC |
| Oct 17, 20254:48 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 4.40%1.19M shares | −0.80 ppfrom 5.20%Below 5% | Oct 15, 2025 | SEC |
| Oct 17, 20254:45 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 5.20%1.41M shares | −4.79 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Aug 14, 20255:59 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 3.20%639.1K shares | −6.70 ppfrom 9.90%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20255:28 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 7.60%1.53M shares | −1.50 ppfrom 9.10% | Jun 30, 2025 | SEC |
| Aug 14, 20254:30 PM ET | Canaan XII L.P.and 1 other | 13G/A | 0.00%0 shares | –Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20254:00 PM ET | BCLS Fund III Investments, LP | 13G/A | 9.99%2.50M shares | – | Jun 30, 2025 | SEC |
| Aug 12, 20258:50 PM ET | Vivo Opportunity Fund Holdings, L.P.and 3 others | 13G/A | 4.60%1.18M shares | −0.10 ppfrom 4.70%Below 5% | Jun 30, 2025 | SEC |
| Aug 12, 20259:02 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 4.97%1.10M shares | −4.07 ppfrom 9.04%Below 5% | Jun 30, 2025 | SEC |
| Aug 11, 20254:43 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 13.30%3.37M shares | −2.50 ppfrom 15.80% | Aug 7, 2025 | SEC |
| Jul 30, 20254:14 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G | 5.60%1.13M shares | New | Jul 23, 2025 | SEC |
| Jul 17, 20258:12 PM ET | BlackRock, Inc. | 13G | 5.50%1.11M shares | New | Jun 30, 2025 | SEC |
| Jul 2, 20254:32 PM ET | Commodore Capital LPand 3 others | 13G | 5.50%1.18M shares | New | Jun 25, 2025 | SEC |
| Jun 30, 20255:05 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 15.80%3.37M shares | – | Jun 26, 2025 | SEC |
| May 15, 20255:47 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 9.90%1.10M shares | – | Mar 31, 2025 | SEC |
| May 15, 20254:25 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.25M shares | 0.00 ppfrom 9.99% | Mar 31, 2025 | SEC |
| May 15, 20258:31 AM ET | Vivo Opportunity Fund Holdings, L.P.and 3 others | 13G/A | 4.70%612.3K shares | –Below 5% | Mar 31, 2025 | SEC |
| May 12, 20259:04 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 9.04%990.0K shares | New | Mar 31, 2025 | SEC |
| Apr 16, 20254:56 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 9.10%999.4K shares | – | Apr 9, 2025 | SEC |
| Feb 14, 20254:05 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.09M shares | – | Dec 31, 2024 | SEC |
| Dec 9, 2024 | Vivo Opportunity Fund Holdings, L.P. | 13GOld format | – | New | – | SEC |
| Dec 4, 2024 | Venrock Healthcare Capital Partners III, L.P. | 13GOld format | – | New | – | SEC |
| Dec 3, 2024 | TCG Crossover GP II, LLC | 13GOld format | – | New | – | SEC |
| Nov 26, 2024 | Ra Capital Management, L.P. | 13D/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Jul 29, 2024 | BCLS Fund III Investments, LP | 13GOld format | – | New | – | SEC |
| Jul 29, 2024 | Canaan XII L.P. | 13GOld format | – | New | – | SEC |
| Jul 25, 2024 | Ra Capital Management, L.P. | 13DOld format | – | New | – | SEC |
| Feb 14, 2024 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 15, 2022 | Lytton Laurence W | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Omega Fund V, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Nantahala Capital Management, LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | BB Biotech AG | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Cidara Therapeutics, Inc. shares.
No Form 144 notices for Cidara Therapeutics, Inc. are on file.